Skip to main content
. 2013 Oct 20;2013(10):CD009455. doi: 10.1002/14651858.CD009455.pub2
Study ID Treatment Any AE SAE AE withdrawal Other withdrawal
Brandes 2007 Study 1 (1) naprox 500 mg, n = 361
(2) placebo, n = 365 ≤ 24 h:
(1) 48/361
(2) 45/365 No SAE reported None reported Exclusions ‐ took medication but no evaluable data:
(1) 5
(2) 5
Brandes 2007 Study 2 (1) naprox 500 mg, n = 371
(2) placebo, n = 387 ≤ 24 h:
(1) 52/371
(2) 39/387 No SAE reported None reported Exclusions ‐ took medication but no evaluable data:
(1) 7
(2) 5
Smith 2005 (1) naprox 500
mg, n = 250
(2) placebo, n =
241 AE reported for safety population at 72 h
(1) 55/250
(2) 36/242 None None None reported
Wentz 2008 (1) naprox 825 mg, n = 96
(2) placebo, n = 102
AE reported until 'study discharge'
(1) 22/96
(2) 8/102
None None 16 excluded (10 had no qualifying headache, 3 lost to follow‐up, 1 protocol violation, 2 'other')
AE: adverse event; naprox: naproxen; SAE: serious adverse event.